CLINICAL SIGNS OF CHEMOTHERAPY-INDUCED NEUROPATHY IN CANCER PATIENTS AND PHARMACOTHERAPY CORRECTION OPTIONS
https://doi.org/10.20514/2226-6704-2018-8-2-137-144
Abstract
The study objective was to analyze the clinical signs of chemotherapy-induced neuropathy (CIPN) in cancer patients and explore pharmacotherapy correction options using vitamin B. Materials and design. During Part 1 lasting from May to September 2017, we screened and then enrolled 219 consecutive patients (mean age of 50.4 ± 6.9 years); 105 (46.7%) of them were women undergoing chemotherapy treatment cycles at Samara Regional Oncological Clinic. Through standard-of-care neurological examination and patient responses we defined the clinical signs of polyneuropathy: its localization, primary symptoms, including sensory impairments and/or pain, and then randomized the patients into two groups: group 1 received vitamin B agents, and group 2 received no vitamin B. The patients were observed for 60 days. Results. The incidence of polyneuropathy in oncology patients receiving chemotherapy turns out to be very high. The phenotype of clinical signs and their severity and localization is probably related to the type of the drug agent used. We have proved the efficacy of the step-down therapy with vitamin B agents used to improve clinical signs of polyneuropathy.
About the Authors
I. A. Zolotovskayaia
Samara State Medical University
Russian Federation
Russian Federation
I. L. Davydkin
Samara State Medical University
Russian Federation
Russian Federation
T. M. Lokshtanova
Samara State Medical University
Russian Federation
Russian Federation
A. E. Orlov
Samara Regional Oncological Clinic
Russian Federation
Russian Federation
References
1. Beijers A., Mols F., Dercksen D., Driessen C., Vreugdenhil G. Chemotherapy-induced peripheral neuropathy and impacton quality of life after treatment with chemo therapy. J Commun Support Oncol. 2014; 12: 401–406.
2. Bakitas M.A. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nursing research. 2007; 56: 323-31.
3. Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. Journal of palliative medicine. 2010; 13: 1389-91.
4. Mols F., Beijers T., Vreugdenhil G. et al. Chemotherapyinduced peripheral neuropathy and its association with quality of life: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2014; 22; 2261- 9.
5. Seretny M., Currie G.L., Sena E.S., Ramnarine S., Grant R., Mac Leod M.R., et al. Incidence, prevalence, and predictors of chemotherapy induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014; 155(12): 2461–70.
6. Miltenburg N.C., Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014; 40(7): 872-82. doi: 10.1016/j.ctrv.2014.04.004.
7. Argyriou A.A., Polychronopoulos P., Iconomou G. et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer treatment reviews. 2008; 34: 368-77. Majithia N., Loprinzi C.L., Smith T.J. New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment. Oncology (Williston Park). 2016; 30: 1020–9.
8. Chu S.H., Lee Y.J., Lee E.S., Geng Y., Wang X.S., Cleeland C.S. Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer. 2015; 23: 513–24.
9. Hershman D.L., Lacchetti C., Dworkin R.H., Lavoie Smith E.M., Bleeker J., Cavaletti G. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014; 32: 1941–67.
10. Pachman D.R., Watson J.C., Loprinzi C.L. Therapeutic strategies for cancer treatment related peripheral neuropathies. Curr. Treat. Options. Oncol. 2014; 15: 567 — 80.
11. Ewertz M., Qvortrup C., Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015; 54: 587–91.
12. Beijers A.J., Jongen J.L., Vreugdenhil G. Chemotherapyinduced neurotoxicity: the value of neuroprotective strategies. Neth. J. Med. 2012; 70(1): 18–25.
13. Mols F., Beijers T., Vreugdenhil G., van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014; 22: 2261–9.
14. Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J. Palliat. Med.2010; 13(11): 1389–1391
15. Brundage M.Gropp M, Mefti F., Mann K., Lund B., Gebski V., Wolfram G., Reed N., Pignata S., Ferrero A., Brown C., Eisenhauer E., Pujade-Lauraine E. Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial. Ann. Oncol. 2012; 23(8): 2020-7. doi: 10.1093/annonc/mdr583.
16. Cavaletti G., Marmiroli P. Chemotherapy-induced peripheral neuro toxicity. Curr. Opin. Neurol. 2015; 28 (5): 500-7. doi: 10.1097/WCO.0000000000000234.
17. Reeves B.N., Dakhil S.R., Sloan J.A. et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012; 118(20): 5171-8. doi: 10.1002/cncr.27489.
18. Hershman D.L., Weimer L.H., Wang A. et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast. Cancer. Res. Treat. 2011; 125(3): 767-74. doi: 10.1007/s10549-010-1278-0.
19. Mohty B., El-Cheikh J., Yakoub-Agha I et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311-9. doi: 10.3324/haematol.2009.012674.
20. Pachman D.R., Qin R., Seisler D.K., Smith E.M., Beutler A.S., Ta L.E., Lafky J.M., Wagner-Johnston N.D., Ruddy K.J., Dakhil S., Staff N.P., Grothey A., Loprinzi C.L. Clinical course of oxaliplatin induced neuropathy: results from the randomizedphase III trial N08CB (alliance). J. Clin. Oncol. 2015; 33(30): 3416-22. doi: 10.1200/ JCO.2014.58.8533.
21. Kidwell K.M., Yothers G., Ganz P.A., et al. Long term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovor in as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS- 01. Cancer. 2012; 118(22): 5614-22. doi: 10.1002/cncr.27593.
22. Mols F., Beijers T., Lemmens V. et al: Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. J. Clin. Oncol.2013; 31: 2699-2707.
23. Tofthagen C., Donovan K.A., Morgan M.A., et al: Oxaliplatininduced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Supp. Care Cancer. 2013; 21: 3307-3313.
24. Wolf S.L., Barton D.L., Qin R., Wos E.J., Sloan J.A., Liu H. et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapyinduced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012; 20(3): 625–32.
25. Cavaletti G., Marmiroli P. Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. Expert Opin Pharmacother. 2018; 19(2): 113-121. doi: 10.1080/14656566.2017.
26. Ghavanini A.A., Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J. Clin Neuromuscul Dis. 2014; 16(1): 25–31.
27. Shenoy A.M. An asymmetric sensory polyneuropathy related to thiamine deficiency from a gluten-free diet. J. Clin Neuromuscul Dis. 2015; 16(4): 224–6.
28. Soloman L. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer. 2016 Aug; 24(8): 3489-94. doi: 10.1007/s00520-016-3175-5
29. Schloss J.M., Colosimo M., Airey C., Vitetta L. Chemotherapy in duced peripheral neuropathy (CIPN) and vitamin B12 deficiency. Support Care Cancer. 2015 Jul; 23(7): 1843- 50. doi: 10.1007/s00520-015-2725-6.
30. Schloss J., Colosimo M.B. Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy Curr. Oncol. Rep. 2017; 19(12): 76. doi: 10.1007/s11912-017-0636-z.
Review
For citations:
Zolotovskayaia I.A., Davydkin I.L., Lokshtanova T.M., Orlov A.E. CLINICAL SIGNS OF CHEMOTHERAPY-INDUCED NEUROPATHY IN CANCER PATIENTS AND PHARMACOTHERAPY CORRECTION OPTIONS. The Russian Archives of Internal Medicine. 2018;8(2):137-144. https://doi.org/10.20514/2226-6704-2018-8-2-137-144
Views:
1310
Email this article 